Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Juan Tavera"'
Autor:
Kellie Ryan, Daniel McHugh, Christopher R. Frei, Ricardo Uribe, Snegha Ananth, Samantha Galley, Courtney Baus, Zohra Nooruddin, Juan Tavera, Michelle Janania-Martinez, David Gregorio, Manuel Ricardo Espinoza-Gutarra, Michael M. Song, Kathleen Franklin, Chengwen Teng, Prathibha Surapaneni, Obiageri O Obodozie-Ofoegbu, Xavier Jones, Hannah Le
Publikováno v:
Leukemia & Lymphoma. 62:1664-1673
The US veteran population has a high proportion of chronic lymphocytic leukemia (CLL) risk factors. Using the Veterans Health Administration (VHA) population, we conducted a retrospective chart review of 1205 CLL patients who initiated treatment with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38e7d50290aa01bb234afc7ead5b2926
https://doi.org/10.1080/10428194.2021.1876863
https://doi.org/10.1080/10428194.2021.1876863
Publikováno v:
EUROPEAN RESEARCH STUDIES JOURNAL. :493-517
Purpose: The aim of this article is to analyze the interaction between key knowledge management (KM) maturity areas: Strategy, Culture, Technology and Knowledge Processes. Design/methodology/approach: Structural equations by the partial least squares
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::37dd997955167b5484cce2880401800e
https://doi.org/10.35808/ersj/1525
https://doi.org/10.35808/ersj/1525
Autor:
Prathibha Surapaneni, Zohra Nooruddin, Hannah Le, Manuel Ricardo Espinoza-Gutarra, Daniel McHugh, Juan Tavera, Samantha Galley, Kellie Ryan, Michael Song, Chengwen Teng, Kathleen Franklin, David Gregorio, Snegha Ananth, Xavier Jones, Christopher R. Frei, Ricardo Uribe, Michelle Janania Martinez, Obiageri O Obodozie-Ofoegbu
Publikováno v:
Journal of Clinical Oncology. 38:252-252
252 Background: Previously, we reported that adverse events (AEs) were the top reason for dose reductions in VHA patients on novel agents. Some AEs might be problematic but might not directly lead to dose reduction; however, these concomitant AEs sho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8a4d20969d77c326e68719e7822763e5
https://doi.org/10.1200/jco.2020.38.29_suppl.252
https://doi.org/10.1200/jco.2020.38.29_suppl.252
Autor:
Christopher R. Frei, Zohra Nooruddin, Kathleen Franklin, Cynthia Elesinmogun, Manuel Ricardo Espinoza-Gutarra, Daniel McHugh, Ricardo Uribe, Xavier Jones, Snegha Ananth, Samantha Galley, Prathibha Surapaneni, Hannah Le, Juan Tavera, Michelle Janania Martinez, Obiageri O Obodozie-Ofoegbu, Chengwen Teng, David Gregorio, Michael Song
Publikováno v:
Blood. 134:795-795
Introduction : CLL is the most common chronic leukemia in the US, with nearly 20,000 new cases expected annually. Novel agents, such as ibrutinib, idelalisib, and venetoclax, have been approved in recent years and provide oral options for CLL. Howeve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::137fde8b8f0d50d007224070b62bd57a
https://doi.org/10.1182/blood-2019-122434
https://doi.org/10.1182/blood-2019-122434